Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;34(1):e14633.
doi: 10.1111/dth.14633. Epub 2020 Dec 15.

Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration

Hamidreza Mahmoudi  1 , Soheil Tavakolpour  1   2 , Kamran Balighi  1 , Ali Salehi Farid  1 , Ali Nili  1 , Delnavaz Jan  1 , Maryam Daneshpazhooh  1
Affiliations
Review

Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration

Hamidreza Mahmoudi et al. Dermatol Ther. 2021 Jan.

Abstract

Pemphigus Vulgaris (PV) is a rare autoimmune blistering disease, which mainly causes mucosal and/or cutaneous lesions. In June 2018, FDA approved Rituximab (RTX)-a B-cell depleting agent-for the management of patients with moderate-to-severe pemphigus. Although the majority of patients respond well to this drug, some do not reach complete remission with a single cycle of RTX. In this review, following an overview of RTX and its clinical outcomes, we have focused on the possible outcomes after RTX therapy in patients with PV. The response is defined into four main categories; complete responders, partial responders, nonresponders, and paradoxical reactions, based on three possibilities of reaching the consolidation phase after 3 months, reaching remission until 6 months, and the ability of corticosteroid tapering in 6 months after RTX administration. Concerning the safety of RTX, three categories of infusion reactions, short and long-term side effects are discussed. Additionally, we have suggested approaches for the evaluation of clinical and serological responses at different critical time-points, including 1, 2, 3, and 6 months after RTX administration. Finally, available markers to predict the response to RTX and research gaps in the field of RTX therapy have been summarized.

Keywords: anti-cd20 monoclonal antibody; pemphigus; rituximab; safety; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882-894.
    1. Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.
    1. Mahmoudi H, Ebrahimi E, Daneshpazhooh M, et al. Single-nucleotide polymorphisms associated with pemphigus vulgaris: potent markers for better treatment and personalized medicine. Int J Immunogenet. 2020;47(1):41-49.
    1. Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res. 2018;310(2):95-106.
    1. Yoshida K, Takae Y, Saito H, et al. Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus. J Am Acad Dermatol. 2005;52(5):839-845.

LinkOut - more resources